CompletedPHASE1, PHASE2NCT02416622

Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)

Studying X-linked retinoschisis

Last synced from ClinicalTrials.gov May 4, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Beacon Therapeutics
Principal Investigator: Theresa Heah, MD, md
Applied Genetics Technologies Corporation
Intervention: rAAV2tYF-CB-hRS1(biological)
Enrollment: 27 enrolled
Eligibility: 6 years · MALE
Timeline: 2015 – 2023

Study locations (9)

University of California San Francisco, Dept. of Ophthalmology, San Francisco, California, United States
University of Miami - Miller School of Medicine Bascom Palmer Eye Institute, Miami, Florida, United States
The Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland, United States
Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
University of Michigan Kellogg Eye Center, Ann Arbor, Michigan, United States
Duke Eye Center, Duke University Medical Center, Durham, North Carolina, United States
Casey Eye Institute, Oregon Health and Sciences University, Portland, Oregon, United States
Retina Foundation of the Southwest, Dallas, Texas, United States
Baylor College of Medicine, Alkek Eye Center, Houston, Texas, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02416622 on ClinicalTrials.gov

Other trials for X-linked retinoschisis

Additional recruiting or active studies for the same condition.

See all trials for X-linked retinoschisis →

← Back to all trials